Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gary Wittert

Showing results (151-160 of 161) with videos related to

Pageof 17
Sort By:
Diabetes, Obesity & Metabolism|December 7, 2018
Testosterone therapy to prevent type 2 diabetes mellitus in at-risk men (T4DM): Design and implementation of a double-blind randomized controlled trialGary Wittert, Evan Atlantis, Carolyn Allan, et al.
Clinical Trials (London, England)|October 5, 2019
A high-volume, low-cost approach to participant screening and enrolment: Experiences from the T4DM diabetes prevention trialKaren Bracken, Anthony Keech, Wendy Hague, et al.
Journal of Clinical Epidemiology|May 4, 2019
Telephone call reminders did not increase screening uptake more than SMS reminders: a recruitment study within a trialKaren Bracken, Anthony Keech, Wendy Hague, et al.
Plos One|July 23, 2024
Translation of culturally and contextually informed diabetes training for Aboriginal primary health care providers on Aboriginal client outcomes: Protocol of a cluster randomized crossover trial of effectivenessOdette Pearson, Sana Ishaque, Saravana Kumar, et al.
The Lancet. Diabetes & Endocrinology|December 18, 2020
Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trialGary Wittert, Karen Bracken, Kristy P Robledo, et al.
Cancers|October 14, 2022
Modulation of Plasma Lipidomic Profiles in Metastatic Castration-Resistant Prostate Cancer by SimvastatinBlossom Mak, Hui-Ming Lin, Thy Duong, et al.
European Journal of Endocrinology|December 25, 2024
Predicting type 2 diabetes and testosterone effects in high-risk Australian men: development and external validation of a 2-year risk modelKristy P Robledo, Ian C Marschner, Mathis Grossmann, et al.
Contemporary Clinical Trials|November 20, 2019
A physician-initiated double-blind, randomised, placebo-controlled, phase 2 study evaluating the efficacy and safety of inhibition of NADPH oxidase with the first-in-class Nox-1/4 inhibitor, GKT137831, in adults with type 1 diabetes and persistently elevated urinary albumin excretion: Protocol and statistical considerationsAnne T Reutens, Karin Jandeleit-Dahm, Merlin Thomas, et al.
BMJ Open Diabetes Research & Care|January 8, 2020
Comparing different definitions of prediabetes with subsequent risk of diabetes: an individual participant data meta-analysis involving 76 513 individuals and 8208 cases of incident diabetesCrystal Man Ying Lee, Stephen Colagiuri, Mark Woodward, et al.
Asia-Pacific Journal of Clinical Oncology|September 5, 2020
Young-onset colorectal cancer is associated with a personal history of type 2 diabetesReger R Mikaeel, Erin L Symonds, James Kimber, et al.
Pageof 17

Showing results (151-160 of 161) with videos related to

Sort By:
Pageof 17
Diabetes, Obesity & Metabolism|December 7, 2018
Testosterone therapy to prevent type 2 diabetes mellitus in at-risk men (T4DM): Design and implementation of a double-blind randomized controlled trialGary Wittert, Evan Atlantis, Carolyn Allan, et al.
Clinical Trials (London, England)|October 5, 2019
A high-volume, low-cost approach to participant screening and enrolment: Experiences from the T4DM diabetes prevention trialKaren Bracken, Anthony Keech, Wendy Hague, et al.
Journal of Clinical Epidemiology|May 4, 2019
Telephone call reminders did not increase screening uptake more than SMS reminders: a recruitment study within a trialKaren Bracken, Anthony Keech, Wendy Hague, et al.
Plos One|July 23, 2024
Translation of culturally and contextually informed diabetes training for Aboriginal primary health care providers on Aboriginal client outcomes: Protocol of a cluster randomized crossover trial of effectivenessOdette Pearson, Sana Ishaque, Saravana Kumar, et al.
The Lancet. Diabetes & Endocrinology|December 18, 2020
Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trialGary Wittert, Karen Bracken, Kristy P Robledo, et al.
Cancers|October 14, 2022
Modulation of Plasma Lipidomic Profiles in Metastatic Castration-Resistant Prostate Cancer by SimvastatinBlossom Mak, Hui-Ming Lin, Thy Duong, et al.
European Journal of Endocrinology|December 25, 2024
Predicting type 2 diabetes and testosterone effects in high-risk Australian men: development and external validation of a 2-year risk modelKristy P Robledo, Ian C Marschner, Mathis Grossmann, et al.
Contemporary Clinical Trials|November 20, 2019
A physician-initiated double-blind, randomised, placebo-controlled, phase 2 study evaluating the efficacy and safety of inhibition of NADPH oxidase with the first-in-class Nox-1/4 inhibitor, GKT137831, in adults with type 1 diabetes and persistently elevated urinary albumin excretion: Protocol and statistical considerationsAnne T Reutens, Karin Jandeleit-Dahm, Merlin Thomas, et al.
BMJ Open Diabetes Research & Care|January 8, 2020
Comparing different definitions of prediabetes with subsequent risk of diabetes: an individual participant data meta-analysis involving 76 513 individuals and 8208 cases of incident diabetesCrystal Man Ying Lee, Stephen Colagiuri, Mark Woodward, et al.
Asia-Pacific Journal of Clinical Oncology|September 5, 2020
Young-onset colorectal cancer is associated with a personal history of type 2 diabetesReger R Mikaeel, Erin L Symonds, James Kimber, et al.
Pageof 17